Budget Impact Analysis of Tenecteplase vs. Alteplase for Adults With Acute Ischemic Stroke (AIS) in Greece
Author(s)
Kyriakos Souliotis, PhD1, CHRISTINA GOLNA, LLM, MSc2, Pavlos Golnas, MSc2, Giannis Papageorgiou, MBA3, Nikos Nikas, PharmD3, Christos Smyrnaios, MSc3, Georgios Tsivgoulis, MD, PhD, MSc, FESO, FEAN, FAAN4.
1School of Social and Political Sciences, University of Peloponnese, Corinth, Greece, 2Health Policy Institute, Maroussi, Greece, 3Boehringer Ingelheim Hellas, Athens, Greece, 42nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
1School of Social and Political Sciences, University of Peloponnese, Corinth, Greece, 2Health Policy Institute, Maroussi, Greece, 3Boehringer Ingelheim Hellas, Athens, Greece, 42nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
OBJECTIVES: To investigate the budgetary impact of reimbursing tenecteplase 0.25 mg/kg for the thrombolytic treatment of adults with Acute Ischaemic Stroke (AIS) in Greece.
METHODS: A model developed for the healthcare system in the UK was adapted to calculate the impact on the budget of the third-party payer, namely the National Organization for Healthcare Services Provision (EOPYY), of reimbursing tenecteplase for the treatment of AIS in Greece over a five-year period (2025-2029). Epidemiological data were sourced from the literature and local expert estimates. Cost data were sourced from published sources and are presented in 2024 Euros. Only direct medical costs related to drug acquisition, disease management and adverse events costs, were considered in the analysis. Two market scenarios were compared: a current scenario, where tenecteplase is not reimbursed, and a future scenario, where tenecteplase is reimbursed for up to 68% of eligible patients. Outcomes were incremental cost and total budget impact for all eligible AIS patients.
RESULTS: The total annual number of AIS patients eligible for the intervention was 450. Patients on tenecteplase were estimated to increase from 180 in 2025 to 270 patients in 2029. Budget impact was projected to increase from €12,220 in year 1 to €13,849 in year 5, at a cumulative impact of €65,172 for the 5-year period. Tenecteplase use resulted in savings in both immediate (acute) hospitalization and post event (1st year) hospitalization costs for AIS patients, thus offsetting its acquisition cost.
CONCLUSIONS: This 5-year budget impact analysis suggests that reimbursing tenecteplase as a thrombolytic treatment for AIS patients in Greece results in measurable savings in acute and post event hospitalization costs at a very limited and predictable additional cost for EOPYY.
METHODS: A model developed for the healthcare system in the UK was adapted to calculate the impact on the budget of the third-party payer, namely the National Organization for Healthcare Services Provision (EOPYY), of reimbursing tenecteplase for the treatment of AIS in Greece over a five-year period (2025-2029). Epidemiological data were sourced from the literature and local expert estimates. Cost data were sourced from published sources and are presented in 2024 Euros. Only direct medical costs related to drug acquisition, disease management and adverse events costs, were considered in the analysis. Two market scenarios were compared: a current scenario, where tenecteplase is not reimbursed, and a future scenario, where tenecteplase is reimbursed for up to 68% of eligible patients. Outcomes were incremental cost and total budget impact for all eligible AIS patients.
RESULTS: The total annual number of AIS patients eligible for the intervention was 450. Patients on tenecteplase were estimated to increase from 180 in 2025 to 270 patients in 2029. Budget impact was projected to increase from €12,220 in year 1 to €13,849 in year 5, at a cumulative impact of €65,172 for the 5-year period. Tenecteplase use resulted in savings in both immediate (acute) hospitalization and post event (1st year) hospitalization costs for AIS patients, thus offsetting its acquisition cost.
CONCLUSIONS: This 5-year budget impact analysis suggests that reimbursing tenecteplase as a thrombolytic treatment for AIS patients in Greece results in measurable savings in acute and post event hospitalization costs at a very limited and predictable additional cost for EOPYY.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE99
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)